Tobacco and alcohol as risk factors for pancreatic cancer.

Best Pract Res Clin Gastroenterol

Department of Surgery, University of Auckland, Auckland, New Zealand. Electronic address:

Published: October 2017

Pancreatic cancer is projected to become the leading cause of cancer deaths by 2050. The risk for pancreatic cancer may be reduced by up to 27% by modifying lifestyle risk factors, most notably tobacco smoking. Based on analysis of more than 2 million unselected individuals from general population, this article quantified the risk of pancreatic cancer in relation to lifelong tobacco smoking and alcohol consumption status, both alone and in combination. It also provided a state-of-the-art review of animal studies on the effect of tobacco smoke and alcohol on genetically engineered mouse models of pancreatic precursor lesions, as well as the role of immune microenvironment in pancreatic carcinogenesis activated by tobacco and alcohol.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747325PMC
http://dx.doi.org/10.1016/j.bpg.2017.09.001DOI Listing

Publication Analysis

Top Keywords

pancreatic cancer
16
tobacco alcohol
8
risk factors
8
risk pancreatic
8
tobacco smoking
8
pancreatic
6
tobacco
5
cancer
5
risk
4
alcohol risk
4

Similar Publications

Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma.

J Clin Invest

January 2025

Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Metabolic reprogramming shapes tumor microenvironment (TME) and may lead to immunotherapy resistance in pancreatic ductal adenocarcinoma (PDAC). Elucidating the impact of pancreatic cancer cell metabolism in the TME is essential to therapeutic interventions. "Immune cold" PDAC is characterized by elevated lactate levels resulting from tumor cell metabolism, abundance of pro-tumor macrophages, and reduced cytotoxic T cell in the TME.

View Article and Find Full Text PDF

Dynamic Coupling of MAPK Signaling to the Guanine Nucleotide Exchange Factor GEF-H1.

Onco Targets Ther

January 2025

Department of Pharmacology, adMare BioInnovations, Montréal, Quebec, H4S 1Z9, Canada.

The gene is nearly ubiquitously subjected to activating mutation in pancreatic adenocarcinomas (PDAC), occurring at a frequency of over 90% in tumors. Mutant KRAS drives sustained signaling through the MAPK pathway to affect frequently disrupted cancer phenotypes including transcription, proliferation and cell survival. Recent research has shown that PDAC tumor growth and survival required a guanine nucleotide exchange factor for RAS homolog family member A (RhoA) called GEF-H1.

View Article and Find Full Text PDF

Pancreatic cancer (PC) remains one of the most lethal malignancies, primarily due to its intrinsic resistance to conventional therapies. MicroRNAs (miRNAs), key regulators of gene expression, have been identified as crucial modulators of drug resistance mechanisms in this cancer type. This review synthesizes recent advancements in our understanding of how miRNAs influence treatment efficacy in PC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!